Shares of Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $193.64, but opened at $175.50. Nutex Health shares last traded at $178.7460, with a volume of 33,018 shares trading hands.
Analyst Upgrades and Downgrades
Several research firms have issued reports on NUTX. LADENBURG THALM/SH SH started coverage on Nutex Health in a research note on Monday, October 26th. They set a "buy" rating and a $336.00 price objective for the company. Lake Street Capital reissued a "buy" rating and set a $310.00 price objective (up from $235.00) on shares of Nutex Health in a report on Tuesday, August 11th. Zacks Research downgraded shares of Nutex Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 6th. Weiss Ratings raised shares of Nutex Health from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, October 6th. Finally, Wall Street Zen lowered shares of Nutex Health from a "buy" rating to a "hold" rating in a report on Saturday, October 31st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $323.67.
Check Out Our Latest Report on Nutex Health
Nutex Health Trading Down 5.9%
The business has a 50 day simple moving average of $203.37 and a 200 day simple moving average of $151.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.00 and a quick ratio of 4.96. The company has a market cap of $1.25 billion, a price-to-earnings ratio of 7.21 and a beta of 0.66.
Nutex Health (NASDAQ:NUTX - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $5.71 earnings per share for the quarter, beating analysts' consensus estimates of $5.54 by $0.17. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%. The company had revenue of $217.61 million during the quarter, compared to analyst estimates of $214.82 million. As a group, equities analysts forecast that Nutex Health Inc. will post 26.65 EPS for the current year.
Insider Buying and Selling
In other Nutex Health news, Director Scott Saunders sold 203 shares of the business's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $214.25, for a total value of $43,492.75. Following the completion of the transaction, the director directly owned 400 shares of the company's stock, valued at approximately $85,700. The trade was a 33.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 44.68% of the stock is currently owned by corporate insiders.
Institutional Trading of Nutex Health
Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Nutex Health during the 2nd quarter worth approximately $69,612,000. Winmill & CO. Inc. acquired a new position in Nutex Health in the second quarter valued at approximately $11,168,000. Empowered Funds LLC acquired a new position in Nutex Health in the second quarter valued at approximately $7,720,000. Bank of New York Mellon Corp acquired a new position in Nutex Health in the second quarter valued at approximately $3,956,000. Finally, Bridge City Capital LLC bought a new position in Nutex Health in the third quarter valued at approximately $3,918,000. 5.32% of the stock is owned by institutional investors.
About Nutex Health
(
Get Free Report)
Nutex Health, Inc NASDAQ: NUTX is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.
Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.